The US government's investigation of pharma companies for health care fraud violations has evolved in recent years, shifting from off-label promotion to anti-kickback allegations. And that has led the Department of Justice to pursue new areas of enforcement action.
DOJ Casting Wider Net In Pharma Kickback Probes
Government is pursuing behavior it once would have taken a pass on, former DOJ attorney notes; pharma companies have inked 16 settlements in past year.
